Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alzheimer's drug put to the test against a different dementia

NCT ID NCT00200538

Symptom relief Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether memantine, a drug already used for Alzheimer's disease, can ease symptoms or slow decline in people with frontotemporal dementia. The trial enrolls adults aged 45 to 75 with mild to moderate FTD and compares memantine against a placebo over one year. Neither participants nor doctors know who receives the drug, and the goal is to see whether it is effective and well tolerated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
memantine, a drug that calms overactive brain signals and is already used in Alzheimer's disease
What this could lead to
If memantine helps, it could become one of the few options for easing frontotemporal dementia symptoms, a condition with no approved treatment.
What could go wrong
The trial is small and tests a drug borrowed from Alzheimer's research, so it may not work for a different form of dementia. Memantine can cause dizziness, headache, or confusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

52 people

The number who actually took part.

Start date

Sep 2005

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with FTD based on the criteria defined by the Lund and Manchester groups' consensus statement (revised in 1998), whose disease has been progressing during the last year. * MMSE score of 19 or higher * Men and women aged 45 to 75 years * Without speech, visuospatial, or episodic memory impairments Exclusion Criteria: * Age \> 76 years * Illiterate or misunderstanding patients * Patients with cancer, heart disease, lung disease, kidney disease (creatinine \> 200 mg/dL), or epilepsy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dementia frontotemporal dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia

Contacts and locations

Locations

  • Martine Vercelletto

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.